This baseline risk means that people prescribed Wegovy may already have elevated thrombotic risk due to their weight status, rather than the medication itself
Multiple injection points ensure even distribution
Leistra MHG, Markwell PJ, Willemse T
The complete selection process, including the number of records identified, screened, and excluded with explicit reasons (separated for preclinical and clinical/epidemiological literature), is documented in the PRISMA flow diagram (Figure 1)
Our studys emphasis on direct cardiac and hepatic mechanisms, independent of significant weight loss, strengthens the rationale for exploring lower doses of GLP-1RAs in these diverse cardiovascular conditions to potentially maximize benefits while minimizing metabolic side effects